- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Roger Adsett, Shire
S
Roger Adsett
VP and General Manager, Gastroenterology, Shire
NOTED FOR: Strong leadership, building blockbuster brands
VISION: "Explain it so others internalize—not recite—it"
Roger Adsett knows big brands. He cut his teeth at Astra Merck, heading up marketing for Nexium, then moved to England to serve as global brand director for AstraZenica's Symbicort. Now re-settled in the Northeast corridor, he's translating marketing savvy and global know-how to Shire's GI business—with good results. Last year's launch of Lialda sent business soaring, without cannibalizing Pentasa sales. Shire brands now serve more than a quarter of the oral mesalamine market. And with a co-promotion deal signed with TAP, Adsett will bring his blockbuster mindset to the realm of specialty sales.
Roger Adsett
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
